Shopping Cart 0
Cart Subtotal
USD 0

Cipla Ltd (CIPLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, neurological, ophthalmic, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla also manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, North America, South Africa and major regulated and emerging markets. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd (CIPLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Cipla Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17

Cipla Acquires Product Line from Camber Pharma 18

Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19

Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20

Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21

Private Equity 22

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22

FIL Capital to Invest in Cipla Health 24

Partnerships 25

Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25

MannKind to Enter into Marketing and Distribution Agreement with Cipla 26

Cipla and Roche Products Enter into Distribution Agreement 27

Cipla and Novartis May Enter into Co-Marketing Agreement 28

Cipla Enters into Distribution Agreement with BioQ Pharma 29

Cipla to Form Joint Venture with Biopharm 30

Cipla Enters into Distribution Agreement with Serum Institute 31

Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32

Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33

Cipla Enters into Distribution Agreement with Serum Institute of India 34

Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35

Cipla Enters into Agreement with S&D Pharma 36

Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37

Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38

Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40

Licensing Agreements 41

Cipla Receives Rights from MSN Laboratories 41

Cipla Enters into Licensing Agreement with Stempeutics 42

Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43

Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46

Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47

Gilead Sciences Enters into Licensing Agreement with Cipla 48

Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52

Equity Offering 54

Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54

Cipla to Raise USD293.2 Million in Public Offering of Securities 55

Debt Offering 56

Cipla to Raise USD293.2 Million in Debt Offering 56

Acquisition 57

Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57

PharmaS to Acquire Cipla Croatia from Cipla Holding 58

Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59

Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60

Allergan Acquires Chase Pharma 61

Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62

Cipla Divests 25% Stake in BioMab for USD25.8 Million 63

Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64

Cipla to Acquire Duomed Produtos 65

Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66

Cipla Acquires Remaining 75% Stake in MabPharm 67

Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68

Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69

Cipla Acquires Celeris, Medical Products Distributor 70

Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For USD 15 Million 71

Cipla Completes Acquisition Of Cipla Medpro South Africa For USD 512 Million 72

Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74

Cipla Ltd-Key Competitors 75

Cipla Ltd-Key Employees 76

Cipla Ltd-Locations And Subsidiaries 77

Head Office 77

Other Locations & Subsidiaries 77

Recent Developments 80

Strategy And Business Planning 80

Jul 13, 2018: Cipla Opens Up To Crowd Sourcing Innovation 80

Financial Announcements 82

Nov 07, 2017: Cipla Q2 FY18 Results Demonstrate Strong Growth Across Businesses and the Benefit of Operating Leverage 82

Aug 11, 2017: Cipla Announces Q1FY 18 Results 83

May 25, 2017: Cipla announces Q4 & FY 17 results Continued strong performance across key markets 84

Corporate Communications 85

Jan 09, 2017: Cipla appoints Peter Lankau as an Independent Director on its Board 85

Legal and Regulatory 86

Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 86

Government and Public Interest 87

Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA 87

Product News 88

Feb 17, 2017: Cipla launches Hepatitis B vaccine in India 88

Other Significant Developments 89

Jun 26, 2018: Consumers need to understand the risks associated with using medication to combat pain 89

Jun 12, 2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda 90

Appendix 91

Methodology 91

About GlobalData 91

Contact Us 91

Disclaimer 91


List Of Figure

List of Figures

Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Cipla Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cipla Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17

Cipla Acquires Product Line from Camber Pharma 18

Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19

Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20

Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22

FIL Capital to Invest in Cipla Health 24

Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25

MannKind to Enter into Marketing and Distribution Agreement with Cipla 26

Cipla and Roche Products Enter into Distribution Agreement 27

Cipla and Novartis May Enter into Co-Marketing Agreement 28

Cipla Enters into Distribution Agreement with BioQ Pharma 29

Cipla to Form Joint Venture with Biopharm 30

Cipla Enters into Distribution Agreement with Serum Institute 31

Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32

Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33

Cipla Enters into Distribution Agreement with Serum Institute of India 34

Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35

Cipla Enters into Agreement with S&D Pharma 36

Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37

Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38

Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40

Cipla Receives Rights from MSN Laboratories 41

Cipla Enters into Licensing Agreement with Stempeutics 42

Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43

Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46

Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47

Gilead Sciences Enters into Licensing Agreement with Cipla 48

Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52

Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54

Cipla to Raise USD293.2 Million in Public Offering of Securities 55

Cipla to Raise USD293.2 Million in Debt Offering 56

Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57

PharmaS to Acquire Cipla Croatia from Cipla Holding 58

Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59

Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60

Allergan Acquires Chase Pharma 61

Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62

Cipla Divests 25% Stake in BioMab for USD25.8 Million 63

Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64

Cipla to Acquire Duomed Produtos 65

Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66

Cipla Acquires Remaining 75% Stake in MabPharm 67

Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68

Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69

Cipla Acquires Celeris, Medical Products Distributor 70

Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For USD 15 Million 71

Cipla Completes Acquisition Of Cipla Medpro South Africa For USD 512 Million 72

Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74

Cipla Ltd, Key Competitors 75

Cipla Ltd, Key Employees 76

Cipla Ltd, Subsidiaries 77

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cipla Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, neurological, ophthalmic, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla also manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, North America, South Africa and major regulated and emerging markets. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd (CIPLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Cipla Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17

Cipla Acquires Product Line from Camber Pharma 18

Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19

Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20

Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21

Private Equity 22

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22

FIL Capital to Invest in Cipla Health 24

Partnerships 25

Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25

MannKind to Enter into Marketing and Distribution Agreement with Cipla 26

Cipla and Roche Products Enter into Distribution Agreement 27

Cipla and Novartis May Enter into Co-Marketing Agreement 28

Cipla Enters into Distribution Agreement with BioQ Pharma 29

Cipla to Form Joint Venture with Biopharm 30

Cipla Enters into Distribution Agreement with Serum Institute 31

Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32

Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33

Cipla Enters into Distribution Agreement with Serum Institute of India 34

Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35

Cipla Enters into Agreement with S&D Pharma 36

Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37

Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38

Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40

Licensing Agreements 41

Cipla Receives Rights from MSN Laboratories 41

Cipla Enters into Licensing Agreement with Stempeutics 42

Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43

Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46

Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47

Gilead Sciences Enters into Licensing Agreement with Cipla 48

Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52

Equity Offering 54

Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54

Cipla to Raise USD293.2 Million in Public Offering of Securities 55

Debt Offering 56

Cipla to Raise USD293.2 Million in Debt Offering 56

Acquisition 57

Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57

PharmaS to Acquire Cipla Croatia from Cipla Holding 58

Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59

Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60

Allergan Acquires Chase Pharma 61

Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62

Cipla Divests 25% Stake in BioMab for USD25.8 Million 63

Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64

Cipla to Acquire Duomed Produtos 65

Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66

Cipla Acquires Remaining 75% Stake in MabPharm 67

Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68

Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69

Cipla Acquires Celeris, Medical Products Distributor 70

Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For USD 15 Million 71

Cipla Completes Acquisition Of Cipla Medpro South Africa For USD 512 Million 72

Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74

Cipla Ltd-Key Competitors 75

Cipla Ltd-Key Employees 76

Cipla Ltd-Locations And Subsidiaries 77

Head Office 77

Other Locations & Subsidiaries 77

Recent Developments 80

Strategy And Business Planning 80

Jul 13, 2018: Cipla Opens Up To Crowd Sourcing Innovation 80

Financial Announcements 82

Nov 07, 2017: Cipla Q2 FY18 Results Demonstrate Strong Growth Across Businesses and the Benefit of Operating Leverage 82

Aug 11, 2017: Cipla Announces Q1FY 18 Results 83

May 25, 2017: Cipla announces Q4 & FY 17 results Continued strong performance across key markets 84

Corporate Communications 85

Jan 09, 2017: Cipla appoints Peter Lankau as an Independent Director on its Board 85

Legal and Regulatory 86

Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 86

Government and Public Interest 87

Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA 87

Product News 88

Feb 17, 2017: Cipla launches Hepatitis B vaccine in India 88

Other Significant Developments 89

Jun 26, 2018: Consumers need to understand the risks associated with using medication to combat pain 89

Jun 12, 2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda 90

Appendix 91

Methodology 91

About GlobalData 91

Contact Us 91

Disclaimer 91


List Of Figure

List of Figures

Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Cipla Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Cipla Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17

Cipla Acquires Product Line from Camber Pharma 18

Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19

Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20

Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22

FIL Capital to Invest in Cipla Health 24

Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25

MannKind to Enter into Marketing and Distribution Agreement with Cipla 26

Cipla and Roche Products Enter into Distribution Agreement 27

Cipla and Novartis May Enter into Co-Marketing Agreement 28

Cipla Enters into Distribution Agreement with BioQ Pharma 29

Cipla to Form Joint Venture with Biopharm 30

Cipla Enters into Distribution Agreement with Serum Institute 31

Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32

Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33

Cipla Enters into Distribution Agreement with Serum Institute of India 34

Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35

Cipla Enters into Agreement with S&D Pharma 36

Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37

Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38

Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40

Cipla Receives Rights from MSN Laboratories 41

Cipla Enters into Licensing Agreement with Stempeutics 42

Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43

Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45

Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46

Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47

Gilead Sciences Enters into Licensing Agreement with Cipla 48

Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50

Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52

Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54

Cipla to Raise USD293.2 Million in Public Offering of Securities 55

Cipla to Raise USD293.2 Million in Debt Offering 56

Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57

PharmaS to Acquire Cipla Croatia from Cipla Holding 58

Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59

Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60

Allergan Acquires Chase Pharma 61

Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62

Cipla Divests 25% Stake in BioMab for USD25.8 Million 63

Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64

Cipla to Acquire Duomed Produtos 65

Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66

Cipla Acquires Remaining 75% Stake in MabPharm 67

Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68

Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69

Cipla Acquires Celeris, Medical Products Distributor 70

Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For USD 15 Million 71

Cipla Completes Acquisition Of Cipla Medpro South Africa For USD 512 Million 72

Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74

Cipla Ltd, Key Competitors 75

Cipla Ltd, Key Employees 76

Cipla Ltd, Subsidiaries 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cipla Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.